161-LB: Role of Child Physical Activity and Sleep Efficiency in Relation to Prenatal Exposure to Gestational Diabetes on Adiposity

Introduction: Little is known on the role of child physical activity (PA) and sleep in relation to maternal gestational diabetes mellitus (GDM) and child adiposity. We explored these relationships using data collected from the BrainChild Study. Method: Data included 88 children (mean ± SD, age 9.5 ± 1.7 years; 52% GDM exposed; 56% female) born at Kaiser Permanente Southern California. GDM exposure was obtained from electronic medical records. Anthropometric measurements, time spent in moderate and vigorous PA and actigraphy-based sleep parameters were measured during daily life for 7 days using wrist-worn accelerometers. Results: GDM exposed vs. unexposed children had higher BMI z-scores (1.3 ± 1.0 vs. 0.7 ± 1.1, p=0.015), total body fat (29.7 ± 9.6 vs. 25.0 ± 8.3%, p=0.017) and waist to height ratios (WHR) (0.52 ± 0.08 vs. 0.47 ± 0.07, p=0.002). Linear regression showed that children who engaged in more VPA had lower measures of adiposity, independent of age and sex (BMI z-score: β=-0.39, p=0.033; body fat%: β=-3.25, p=0.037; WHR: β=-0.23, p=0.068). Further adjusting for sleep efficiency did not affect the results. Similar patterns were observed for MVPA but were not significant. There was no interaction between GDM exposure and PA on adiposity. Sleep efficiency was not associated with adiposity, but there was a significant interaction between GDM exposure and sleep efficiency on child adiposity (p=0.042). GDM exposed children who had better sleep efficiency had marginally lower body fat (β=-0.56, p=0.098), while this relationship was not observed in unexposed children (β=0.50, p=0.14). Conclusion: Our findings demonstrate that VPA is associated with lower child adiposity measures regardless of GDM exposure, and sleep efficiency is associated with lower adiposity among GDM exposed children. These findings suggest that strategies to increase VPA and improve sleep efficiency may be beneficial for ameliorating the adverse effects of GDM exposure on child adiposity. Disclosure J. M. Alves: None. A. W. Defendis: None. T. Chow: None. S. T. Nguyen-rodriguez: None. A. Xiang: None. K. A. Page: None. Funding American Diabetes Association (1-14-ACE-36 to K.A.P.); National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (R01DK116858)